SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives

被引：18

作者：

Garla, Vishnu Vardhan ^{[1
,2
]}

Butler, Javed ^{[3
]}

Lien, Lillian F. ^{[1
]}

机构：

[1] Univ Mississippi, Med Ctr, Endocrinol Metab & Diabet, Dept Internal Med, Jackson, MS 39216 USA

[2] Univ Mississippi, Med Ctr, Mississippi Ctr Clin & Translat Res, Jackson, MS 39216 USA

[3] Univ Mississippi, Dept Internal Med, Med Ctr, Jackson, MS USA

来源：

CURRENT CARDIOLOGY REPORTS | 2021年 / 23卷 / 06期

关键词：

Sodium-glucose cotransporter-2 inhibitors; Heart failure; Hospitalization for heart failure; Major adverse cardiovascular events; Euglycemic diabetic ketoacidosis; COTRANSPORTER; 2; INHIBITOR; TYPE-2; DIABETES-MELLITUS; SODIUM; EMPAGLIFLOZIN; CANAGLIFLOZIN; INFECTIONS; MORTALITY; SAFETY;

D O I：

10.1007/s11886-021-01486-3

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Purpose of Review Heart failure is responsible for a significant part of diabetes-associated cardiovascular mortality and morbidity. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are novel agents approved for the treatment of diabetes mellitus; in recent clinical trials, these agents have shown a significant reduction in cardiovascular death and hospitalization secondary to heart failure. Recent Findings Clinical trials with specific heart failure outcomes have shown the benefit of SGLT-2 inhibitors in reducing the mortality and morbidity associated with heart failure. The guidelines for the management of diabetes mellitus recommend the preferential use of SGLT-2 inhibitors in patients with a history of cardiovascular disease. SGLT-2 inhibitors are potential game changers in the treatment of heart failure. Guidelines for prescription of these agents help assess risk-benefit analysis and personalize treatment for maximal benefit.

引用

页数：9

共 48 条

[41]

SGLT2 Inhibitors: Benefit/Risk Balance [J].

Scheen, Andre J. .

CURRENT DIABETES REPORTS, 2016, 16 (10)

[42]

Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit [J].

Thong, Ken Yan ;

Yadagiri, Mahender ;

Barnes, Dennis Joseph ;

Morris, David Stuart ;

Chowdhury, Tahseen Ahmad ;

Chuah, Ling Ling ;

Robinson, Anthony Michael ;

Bain, Stephen Charles ;

Adamson, Karen Ann ;

Ryder, Robert Elford John .

PRIMARY CARE DIABETES, 2018, 12 (01) :45-50

[43]

U.S. Food and Drug Administration, 2011, ADVISORY COMMITTEE M

[44]

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review [J].

Verma, Subodh ;

McMurray, John J. V. .

DIABETOLOGIA, 2018, 61 (10) :2108-2117

[45]

Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI [10.1056/NEJMoa1812389, 10.1056/NEJMc1902837]

[46]

Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys [J].

Yaribeygi, Habib ;

Katsiki, Niki ;

Butler, Alexandra E. ;

Sahebkar, Amirhossein .

DRUG DISCOVERY TODAY, 2019, 24 (01) :256-262

[47]

Positive Impact of Continuous-Flow Left Ventricular Assist Device Implantation on Glycemic Control in Patients with Type 2 Diabetes Mellitus and Advanced Chronic Systolic Heart Failure [J].

Yen, Debbie C. ;

Watson, Mara H. ;

Burgess, Lindsey D. ;

Kuchibhatla, Maragatha ;

Patel, Chetan B. ;

Campbell, Kristen B. ;

Vora, Alyssa K. .

PHARMACOTHERAPY, 2016, 36 (12) :1210-1216

[48]

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [J].

Fischereder, Michael ;

Schoenermarck, Ulf .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (11) :1092-1093

← 1 2 3 4 5 →